<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1665-1146</journal-id>
<journal-title><![CDATA[Boletín médico del Hospital Infantil de México]]></journal-title>
<abbrev-journal-title><![CDATA[Bol. Med. Hosp. Infant. Mex.]]></abbrev-journal-title>
<issn>1665-1146</issn>
<publisher>
<publisher-name><![CDATA[Instituto Nacional de Salud, Hospital Infantil de México Federico Gómez]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1665-11462016000600397</article-id>
<article-id pub-id-type="doi">10.1016/j.bmhimx.2016.10.001</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Evaluation of the TRPM2 channel as a biomarker in breast cancer using public databases analysis]]></article-title>
<article-title xml:lang="es"><![CDATA[Evaluación del canal TRPM2 como biomarcador en cáncer de mama mediante el análisis de bases de datos públicos]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Sumoza-Toledo]]></surname>
<given-names><![CDATA[Adriana]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Espinoza-Gabriel]]></surname>
<given-names><![CDATA[Mario Iván]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="A a"/>
<xref ref-type="aff" rid="A02"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Montiel-Condado]]></surname>
<given-names><![CDATA[Dvorak]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="A01">
<institution><![CDATA[,Universidad Veracruzana Instituto de Investigaciones Médico-Biológicas ]]></institution>
<addr-line><![CDATA[Veracruz Veracruz]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="A02">
<institution><![CDATA[,Universidad Veracruzana Facultad de Bioanálisis ]]></institution>
<addr-line><![CDATA[Veracruz Veracruz]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="A03">
<institution><![CDATA[,Universidad Autónoma de Nuevo León Facultad de Ciencias Biológicas Laboratorio de Ciencias Genómicas]]></institution>
<addr-line><![CDATA[San Nicolás de los Garza Nuevo León]]></addr-line>
<country>Mexico</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2016</year>
</pub-date>
<volume>73</volume>
<numero>6</numero>
<fpage>397</fpage>
<lpage>404</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S1665-11462016000600397&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S1665-11462016000600397&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S1665-11462016000600397&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract:  Background: Breast cancer is one of the most common malignancies affecting women. Recent investigations have revealed a major role of ion channels in cancer. The transient receptor potential melastatin-2 (TRPM2) is a plasma membrane and lysosomal channel with important roles in cell migration and cell death in immune cells and tumor cells.  Methods: In this study, we investigated the prognostic value of TRPM2 channel in breast cancer, analyzing public databases compiled in Oncomine&#8482; (Thermo Fisher, Ann Arbor, MI) and online Kaplan-Meier Plotter platforms.  Results: The results revealed that TRPM2 mRNA overexpression is significant in situ and invasive breast carcinoma compared to normal breast tissue. Furthermore, multi-gene validation using Oncomine&#8482; showed that this channel is coexpressed with proteins related to cellular migration, transformation, and apoptosis. On the other hand, Kaplan-Meier analysis exhibited that low expression of TRPM2 could be used to predict poor outcome in ER- and HER2+ breast carcinoma patients.  Conclusions: TRPM2 is a promising biomarker for aggressiveness of breast cancer, and a potential target for the development of new therapies.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen:  Introducción: El cáncer de mama es la neoplasia maligna más común que afecta a mujeres. Estudios recientes han revelado un papel importante de los canales iónicos en el cáncer. El receptor de potencial transitorio melastatin-2 (TRPM2) es un canal que se expresa en la membrana plasmática y en los lisosomas; posee funciones importantes en la migración y muerte celular de células inmunes y tumorales.  Métodos: En este estudio se investigó el valor pronóstico del canal TRPM2 en cáncer mama. Se realizó el análisis de bases de datos públicos empleando las plataformas OncomineTM (Thermo Fisher, Ann Arbor, MI) y Kaplan-Meier Plotter.  Resultados: Los resultados mostraron que el mRNA de TRPM2 se sobreexpresa significativamente en los carcinomas de mama in situ e invasivo en comparación con el tejido mamario normal. Además, la validación de múltiples genes empleando OncomineTM reveló que este canal se coexpresa con proteínas relacionadas con la migración celular, la transformación celular y apoptosis. Por otra lado, el análisis de la sobrevivencia promedio usando curvas Kaplan-Meier mostró que la baja expresión de TRPM2 podría utilizarse como un marcador de pronóstico pobre en pacientes con carcinoma de mama receptor de estrógeno negativo (ER-) y receptor 2 del factor de crecimiento epidermal positivo (HER2+).  Conclusiones: El TRPM2 podría emplearse como biomarcador de agresividad en cáncer de mama, y como blanco para el desarrollo de nuevas terapias.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Breast cancer]]></kwd>
<kwd lng="en"><![CDATA[TRPM2]]></kwd>
<kwd lng="en"><![CDATA[Biomarker]]></kwd>
<kwd lng="en"><![CDATA[Ion channel]]></kwd>
<kwd lng="en"><![CDATA[Microarray]]></kwd>
<kwd lng="es"><![CDATA[Cáncer de mama]]></kwd>
<kwd lng="es"><![CDATA[TRPM2]]></kwd>
<kwd lng="es"><![CDATA[Biomarcador]]></kwd>
<kwd lng="es"><![CDATA[Canal iónico]]></kwd>
<kwd lng="es"><![CDATA[Microarreglo]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Cancer hallmarks, biomarkers and breast cancer molecular subtypes]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dai]]></surname>
<given-names><![CDATA[X.]]></given-names>
</name>
<name>
<surname><![CDATA[Xiang]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Bai]]></surname>
<given-names><![CDATA[Z.]]></given-names>
</name>
</person-group>
<source><![CDATA[J Cancer]]></source>
<year>2016</year>
<volume>7</volume>
<page-range>1281-94</page-range></nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Breast cancer intrinsic subtype classification, clinical use and future trends]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dai]]></surname>
<given-names><![CDATA[X.]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
<name>
<surname><![CDATA[Bai]]></surname>
<given-names><![CDATA[Z.]]></given-names>
</name>
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[Y.]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[X.]]></given-names>
</name>
<name>
<surname><![CDATA[Zhan]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<source><![CDATA[Am J Cancer Res]]></source>
<year>2015</year>
<volume>5</volume>
<page-range>2929-43</page-range></nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Breast cancer classification according to immunohistochemical markers: clinicopathologic features and short-term survival analysis in a population-based study from the South of Switzerland]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Spitale]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Mazzola]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Soldini]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[Mazzucchelli]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Bordoni]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<source><![CDATA[Ann Oncol]]></source>
<year>2009</year>
<volume>20</volume>
<page-range>628-35</page-range></nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[TP53 status and response to treatment in breast cancers]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Varna]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Bousquet]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Plassa]]></surname>
<given-names><![CDATA[L.F.]]></given-names>
</name>
<name>
<surname><![CDATA[Bertheau]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Janin]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<source><![CDATA[J Biomed Biotechnol]]></source>
<year>2011</year>
<volume>2011</volume>
</nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Data-driven analysis of TRP channels in cancer: linking variation in gene expression to clinical significance]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Park]]></surname>
<given-names><![CDATA[Y.R.]]></given-names>
</name>
<name>
<surname><![CDATA[Chun]]></surname>
<given-names><![CDATA[J.N.]]></given-names>
</name>
<name>
<surname><![CDATA[So]]></surname>
<given-names><![CDATA[I.]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[H.J.]]></given-names>
</name>
<name>
<surname><![CDATA[Baek]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Jeon]]></surname>
<given-names><![CDATA[J.H.]]></given-names>
</name>
</person-group>
<source><![CDATA[Cancer Genomics Proteomics]]></source>
<year>2016</year>
<volume>13</volume>
<page-range>83-90</page-range></nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Inhibition of the transient receptor potential melastatin-2 channel causes increased DNA damage and decreased proliferation in breast adenocarcinoma cells]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hopkins]]></surname>
<given-names><![CDATA[M.M.]]></given-names>
</name>
<name>
<surname><![CDATA[Feng]]></surname>
<given-names><![CDATA[X.]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Parker]]></surname>
<given-names><![CDATA[L.P.]]></given-names>
</name>
<name>
<surname><![CDATA[Koh]]></surname>
<given-names><![CDATA[D.W.]]></given-names>
</name>
</person-group>
<source><![CDATA[Int J Oncol]]></source>
<year>2015</year>
<volume>46</volume>
<page-range>2267-76</page-range></nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[High expression of transient receptor potential channels in human breast cancer epithelial cells and tissues: correlation with pathological parameters]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dhennin-Duthille]]></surname>
<given-names><![CDATA[I.]]></given-names>
</name>
<name>
<surname><![CDATA[Gautier]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Faouzi]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Guilbert]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Brevet]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Vaudry]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
</person-group>
<source><![CDATA[Cell Physiol Biochem]]></source>
<year>2011</year>
<volume>28</volume>
<page-range>813-22</page-range></nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[TRPM2: a multifunctional ion channel for calcium signalling]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sumoza-Toledo]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Penner]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
</person-group>
<source><![CDATA[J Physiol]]></source>
<year>2011</year>
<volume>589</volume>
<page-range>1515-25</page-range></nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[ONCOMINE: a cancer microarray database and integrated data-mining platform]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rhodes]]></surname>
<given-names><![CDATA[D.R.]]></given-names>
</name>
<name>
<surname><![CDATA[Yu]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Shanker]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
<name>
<surname><![CDATA[Deshpande]]></surname>
<given-names><![CDATA[N.]]></given-names>
</name>
<name>
<surname><![CDATA[Varambally]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Ghosh]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
</person-group>
<source><![CDATA[Neoplasia]]></source>
<year>2004</year>
<volume>6</volume>
<page-range>1-6</page-range></nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Cross-validation of survival-associated biomarkers in gastric cancer using transcriptomic data of 1,065 patients]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Szász]]></surname>
<given-names><![CDATA[A.M.]]></given-names>
</name>
<name>
<surname><![CDATA[Lánczky]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Nagy]]></surname>
<given-names><![CDATA[Á.]]></given-names>
</name>
<name>
<surname><![CDATA[Förster]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Hark]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
<name>
<surname><![CDATA[Green]]></surname>
<given-names><![CDATA[J.E.]]></given-names>
</name>
</person-group>
<source><![CDATA[Oncotarget]]></source>
<year>2016</year>
</nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian cancer using microarray data from 1287 patients]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gyorffy]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
<name>
<surname><![CDATA[Lánczky]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Szállási]]></surname>
<given-names><![CDATA[Z.]]></given-names>
</name>
</person-group>
<source><![CDATA[Endocr Relat Cancer]]></source>
<year>2012</year>
<volume>19</volume>
<page-range>197-208</page-range></nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Intratumoral expression of CCR3 in breast cancer is associated with improved relapse-free survival in luminal-like disease]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gong]]></surname>
<given-names><![CDATA[D.H.]]></given-names>
</name>
<name>
<surname><![CDATA[Fan]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[H.Y.]]></given-names>
</name>
<name>
<surname><![CDATA[Ding]]></surname>
<given-names><![CDATA[K.F.]]></given-names>
</name>
<name>
<surname><![CDATA[Yu]]></surname>
<given-names><![CDATA[K.D.]]></given-names>
</name>
</person-group>
<source><![CDATA[Oncotarget]]></source>
<year>2016</year>
<volume>7</volume>
<page-range>28570-8</page-range></nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Eotaxin-1 promotes prostate cancer cell invasion via activation of the CCR3-ERK pathway and upregulation of MMP-3 expression]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhu]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[Y.]]></given-names>
</name>
</person-group>
<source><![CDATA[Oncol Rep]]></source>
<year>2014</year>
<volume>31</volume>
<page-range>2049-54</page-range></nlm-citation>
</ref>
<ref id="B14">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Role of TRPM in melanocytes and melanoma]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Guo]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
<name>
<surname><![CDATA[Carlson]]></surname>
<given-names><![CDATA[J.A.]]></given-names>
</name>
<name>
<surname><![CDATA[Slominski]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<source><![CDATA[Exp Dermatol]]></source>
<year>2012</year>
<volume>21</volume>
<page-range>650-4</page-range></nlm-citation>
</ref>
<ref id="B15">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Expression-profiling of apoptosis induced by ablation of the long ncRNA TRPM2-AS in prostate cancer cell]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lavorgna]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Chiacchiera]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
<name>
<surname><![CDATA[Briganti]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Montorsi]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
<name>
<surname><![CDATA[Pasini]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[Salonia]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<source><![CDATA[Genom Data]]></source>
<year>2015</year>
<volume>3</volume>
<page-range>4-5</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
